See the DrugPatentWatch profile for ruxolitinib

Ruxolitinib, a drug manufactured by Apotex Corp., is used to treat certain medical conditions. According to the Apotex Corp. website, Ruxolitinib is a Janus kinase (JAK) inhibitor that is used to treat patients with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea [1]. Additionally, Ruxolitinib is also used to treat patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis [1].

Furthermore, DrugPatentWatch.com states that Ruxolitinib is also used to treat steroid-refractory acute graft-versus-host disease in adult and pediatric patients 12 years and older [2].

In summary, Ruxolitinib, manufactured by Apotex Corp., is a JAK inhibitor that is used to treat patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea, as well as patients with intermediate or high-risk myelofibrosis. Additionally, Ruxolitinib is also used to treat steroid-refractory acute graft-versus-host disease in adult and pediatric patients 12 years and older.

Sources:
[1] <https://www.apotexcorp.com/product-details/ruxolitinib-tablets-10mg-and-15mg>
[2] <https://www.drugpatentwatch.com/drugs/ruxolitinib>